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The G4C2-repeat expansion in C9orf72 is the most common known cause of amyotrophic lateral sclerosis and frontotemporal
dementia. The high phenotypic heterogeneity of C9orf72 patients includes a wide range in age of onset, modiﬁers of which are
largely unknown. Age of onset could be inﬂuenced by environmental and genetic factors both of which may trigger DNA
methylation changes at CpG sites. We tested the hypothesis that age of onset in C9orf72 patients is associated with some
common single nucleotide polymorphisms causing a gain or loss of CpG sites and thus resulting in DNA methylation alterations.
Combined analyses of epigenetic and genetic data have the advantage of detecting functional variants with reduced likelihood of
false negative results due to excessive correction for multiple testing in genome-wide association studies. First, we estimated the
association between age of onset in C9orf72 patients (n = 46) and the DNA methylation levels at all 7603 CpG sites available on
the 450 k BeadChip that are mapped to common single nucleotide polymorphisms. This was followed by a genetic association
study of the discovery (n = 144) and replication (n = 187) C9orf72 cohorts. We found that age of onset was reproducibly
associated with polymorphisms within a 124.7 kb linkage disequilibrium block tagged by top-signiﬁcant variation, rs9357140,
and containing two overlapping genes (LOC101929163 and C6orf10). A meta-analysis of all 331 C9orf72 carriers revealed that
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every A-allele of rs9357140 reduced hazard by 30% (P = 0.0002); and the median age of onset in AA-carriers was 6 years later
than GG-carriers. In addition, we investigated a cohort of C9orf72 negative patients (n = 2634) affected by frontotemporal
dementia and/or amyotrophic lateral sclerosis; and also found that the AA-genotype of rs9357140 was associated with a later
age of onset (adjusted P = 0.007 for recessive model). Phenotype analyses detected signiﬁcant association only in the largest
subgroup of patients with frontotemporal dementia (n = 2142, adjusted P = 0.01 for recessive model). Gene expression studies
of frontal cortex tissues from 25 autopsy cases affected by amyotrophic lateral sclerosis revealed that the G-allele of rs9357140 is
associated with increased brain expression of LOC101929163 (a non-coding RNA) and HLA-DRB1 (involved in initiating immune
responses), while the A-allele is associated with their reduced expression. Our ﬁndings suggest that carriers of the rs9357140 GG-
genotype (linked to an earlier age of onset) might be more prone to be in a pro-inﬂammatory state (e.g. by microglia) than AA-
carriers. Further, investigating the functional links within the C6orf10/LOC101929163/HLA-DRB1 pathway will be critical to
better deﬁne age-dependent pathogenesis of frontotemporal dementia and amyotrophic lateral sclerosis.
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Introduction
The G4C2-repeat expansion in C9orf72 is the most
common known cause of amyotrophic lateral sclerosis
(ALS) and frontotemporal dementia (FTD) (DeJesus-
Hernandez et al., 2011; Renton et al., 2011; Gijselinck
et al., 2012) in Caucasians. It accounts for about 37%
familial and 7% sporadic ALS patients; as well as 25%
familial and 6% sporadic FTD patients (Rademakers,
2012) with age and sex dependent disease penetrance
(Murphy et al., 2017). High phenotypic heterogeneity of
C9orf72 patients also includes a wide range in disease
age of onset (27–74 years) and duration (0.5–22 years)
(Gijselinck et al., 2016). Yet, genetic modiﬁers of age of
onset in C9orf72 patients are largely unknown [only the
T-allele of rs1990622 in TMEM106B was associated with
a later age of onset of FTD, but not ALS (Gallagher et al.,
2014; van Blitterswijk et al., 2014)]. Detection of the age of
onset modiﬁer(s) might increase the accuracy of predicting
age of onset in asymptomatic mutation carriers, which is
important for clinical trials focused on early intervention.
Age of onset could be inﬂuenced by genetic and environ-
mental modiﬁers, both of which may trigger epigenetic
changes, such as DNA methylation at CpG sites (Zhang
et al., 2016). Indeed, there is no a strict dichotomy between
action of genetic and epigenetic factors; they often work in
concert. Genome-wide DNA methylation proﬁles of identi-
cal twins are much more similar than between fraternal
siblings (Zhang et al., 2016), demonstrating that many epi-
genetic changes are genetically controlled (e.g. the repeat
expansion causes hypermethylation of the C9orf72 locus
leading to downregulation of C9orf72 expression) (Xi
et al., 2015b; Gijselinck et al., 2016). The DNA methyla-
tion levels of some CpGs are age-related allowing the esti-
mation of DNA methylation age based on the cumulative
assessment of 353 CpGs included on the genome-wide
450K BeadChip. Currently, DNA methylation age is the
most accurate predictor of chronological age across mul-
tiple tissues (Horvath, 2013), but may in fact reﬂect biolo-
gical age better than chronological age. Indeed, we recently
reported that increased DNA methylation age acceleration
(DNA methylation age minus chronological age) is
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associated with earlier age of onset in C9orf72 patients
analysed on the 450K BeadChip after exclusion of CpGs
mapped to common single nucleotide polymorphisms
(SNPs) (Zhang et al., 2017).
CpGs are the most mutable sites in the human genome
because methyl-C can spontaneously deaminate to T (e.g.
35% of all coding mutations occur at CpG sites)
(Lek et al., 2016). Hence, in the current study we tested
the hypothesis that age of onset in C9orf72 patients is
associated with some common SNPs causing a gain or
loss of CpG sites (CpG-SNPs) and thus resulting in DNA
methylation changes. Allele-speciﬁc DNA methylation is
largely attributed to CpG-SNPs (Shoemaker et al., 2010),
which have often been detected within promoter regions,
transcription factor binding sites and DNase I hypersensi-
tive sites (Gagliano et al., 2016), thus regulating the level of
gene expression. CpG-SNPs belong to a group of methyla-
tion quantitative trait loci (Hannon et al., 2016), which are
linked to some mental disorders (Gagliano et al., 2016).
We combined epigenetic and genetic approaches to map
functional variants (CpG-SNPs) associated with age of
onset in C9orf72 carriers. Such a study design reduces
the likelihood of false negative results due to excessive cor-
rection for multiple testing in genome-wide association stu-
dies (GWASs). Our study also includes suggestions on how
the signiﬁcant SNPs exert their effects (e.g. by inﬂuencing
gene expression).
Materials and methods
Participants
Informed consent was obtained from all participants in accord-
ance with the respective ethics review boards. Sample character-
istics are presented in Table 1 and Supplementary Table 1 for
C9orf72 carriers, and Supplementary Table 2 for C9orf72 nega-
tive patients. Brieﬂy, our study included patients diagnosed with
bulbar or limb onset ALS, behavioural FTD (bvFTD), semantic
dementia, progressive non-ﬂuent aphasia (PNFA), and FTD-
ALS. All patients were of Caucasian origin and diagnosed at
hospitals specializing in neurodegenerative disorders using estab-
lished clinical criteria for ALS (Brooks et al., 2000) and FTD
(Neary et al., 1998), including the revised diagnostic criteria for
bvFTD (Rascovsky et al., 2011) and language variants of FTD
(Gorno-Tempini et al., 2011). Age of onset was deﬁned as the
age at which the ﬁrst disease symptoms appeared, including
initial bulbar or limb symptoms in ALS, and cognitive dysfunc-
tion in judgement, language, memory, or changes in behaviour
or personality in FTD. Age of onset was either self-reported (for
ALS) or obtained from unaffected family members (for FTD).
The discovery cohort was recruited from Canada, Italy,
Spain, UK, USA or Argentina and consisted of 144 C9orf72
carriers, including 21 symptomatic and 22 asymptomatic car-
riers from 16 pedigrees. The independent replication cohort
was obtained from centres (different from those that collected
the discovery cohort) participating in the International FTD-
Genomics Consortium (IFGC; https://ifgcsite.wordpress.com/)
(Ferrari et al., 2014). It consisted of 187 unrelated FTD or
FTD-ALS C9orf72 carriers from the USA, Canada, UK,
France, Belgium, Italy, Germany, Spain, Sweden, the
Netherlands and Australia. Information about family related-
ness was obtained from the clinical notes of the neurologists
who collected the samples. In addition, the presence of related-
ness in the replication cohort was previously assessed as part
of a GWAS that identiﬁed and excluded all ﬁrst-degree rela-
tives (through identity by descent for any pair with an estimate
50.125) (Ferrari et al., 2014).
For a follow-up study of unrelated C9orf72 negative
patients, we investigated 2142 FTD and 164 FTD-ALS patients
from the IFGC (Ferrari et al., 2014), as well as 328 sporadic
ALS patients from the ALS clinic at Sunnybrook Health
Sciences Centre, Toronto (Supplementary Table 2), which
also provided frontal cortex from 25 unrelated ALS autopsy
cases without an expansion in C9orf72 (530 repeats) for the
gene expression studies (Supplementary Table 3).
Procedures
Blood genomic DNA was extracted using a QIAGEN kit. First,
we analysed the genome-wide DNA methylation data from the
450K BeadChip (Illumina) that was previously generated using
bisulﬁte converted DNA of 46 Canadian C9orf72 carriers
(Zhang et al., 2017) to discover common CpG-SNPs with
minor allele frequencies 45% that are associated with age of
onset. The raw data were preprocessed and analysed using the
minﬁ package in R-project (Aryee et al., 2014). The b-value was
used to estimate the DNA methylation level of each CpG-site (b-
value of 0: non-methylated; b-value of 1: completely methylated).
All participants of the discovery and replication cohorts
(n = 331) were carriers of an expansion in C9orf72 (430 re-
peats) based on previous analysis by repeat-primed PCR (Ferrari
et al., 2014; Xi et al., 2015b). Genotypes for rs9357140,
rs2143466 and rs1990622 were obtained by Sanger sequencing
in the discovery cohort (Supplementary Table 4). For the
Table 1 Sample characteristics of the discovery and replication C9orf72 datasets
Discovery cohort Replication
cohort
Unrelated
carriers
Symptomatic carriers
from 16 families
Asymptomatic carriers
from 16 families
Unrelated
carriers
Number of cases 101 21 22 187
Sex, male, n (%) 55 (54.4) 10 (47.6) 12 (45.5) 104 (55.6)
Age of onset, years, median (IQR) 59 (54–66) 55 (48–60) NA 58 (51–63)
Age of onset, years, mean (range) 59.82 (37–78) 54.86 (38–73) NA 57.2 (34–80)
NA = not applicable.
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replication dataset, these SNPs together with eight SNPs in
strong linkage disequilibrium (LD) with rs9357140 and
rs2143466 (R24 0.9) were either genotyped or imputed using
the latest data from the Haplotype Reference Consortium
(McCarthy et al., 2016) (Supplementary Table 5).
Genotypes for rs9357140 in a follow-up cohort of 2634
unrelated C9orf72 negative patients with ALS, FTD or FTD-
ALS, were obtained by TaqManTM assay (C___9782529_10,
ThermoFisher Scientiﬁc) for 328 ALS patients, or imputed
from IFGC-GWAS for 2306 FTD and FTD-ALS patients
(Ferrari et al., 2014) using the latest data from the
Haplotype Reference Consortium (McCarthy et al., 2016).
To measure the degree of LD, we extracted R2 values (range
from 0 to 1 with higher values indicating a higher LD) from
the LDlink tool (https://analysistools.nci.nih.gov/LDlink) using
the 1000 Genomes European population data. We searched
for known variants within the boundaries of the LD block
(R24 0.8) tagged by the top signiﬁcant SNP (rs9357140)
using the ‘proxy search’ in LDlink. Functional predictions
for the missense SNPs were based on the PolyPhen-2 and
SIFT data available from the Exome Aggregation
Consortium database (Lek et al., 2016). Using the UCSC
genome browser, the LD-block was also analysed for tran-
scriptional factor binding sites and DNase I hypersensitivity.
To detect genes whose expression is associated with
rs9357140, we searched for expression quantitative trait loci
(eQTL) using Genotype-Tissue Expression (GTEx v7) data from
48 types of human tissues (GTEx Consortium et al., 2017). The
GTEx portal (https://www.gtexportal.org/) was used to analyse
the association between rs9357140 genotypes and gene expres-
sion by a linear regression method. Normalized effect size (NES)
was deﬁned as the slope of the linear regression.
To quantify gene expression, total RNA was extracted from
human frontal cortex of ALS cases without C9orf72 expansions
using the QIAzol plus RNeasy Mini Kit (QIAGEN) and reverse
transcribed to cDNA using oligo dT primers and the
AfﬁnityScript Multiple Temperature cDNA Synthesis Kit
(Agilent Technologies). Quantitative RT-PCR was conducted
for 25 samples (Supplementary Table 3) with an RNA integrity
number 46.5 (based on an Agilent 2100 Bioanalyzer). To select
endogenous control genes for the frontal cortex, we assessed
four housekeeping genes including HPRT1 (MIM: 308000;
Hs99999909_m1), UBC (MIM: 191340; Hs00824723_m1),
B2M (MIM: 109700; Hs99999907_m1), and RPLP0 (MIM:
180510; Hs00420895_gH) (ThermoFisher Scientiﬁc) in nine
samples (n = 3 per each rs9357140 genotype). We used
Normﬁnder (Andersen et al., 2004) to identify the least variable
housekeeping genes (B2M and RPLP0) in our samples
(Supplementary Table 6). We measured expression of HLA-
DRB1 transcript variant 1 (MIM:142857; Hs04192464_mH)
and all C9orf72 transcripts (MIM:614260; Hs00376619_m1)
(ThermoFisher Scientiﬁc) in triplicate for 25 samples with differ-
ent rs9357140 genotypes: AA (n = 9), AG (n = 8) and GG
(n = 8). Relative quantiﬁcation was calculated with the ddCt
method by geometric mean of housekeeping gene expression
(B2M and RPLP0).
Statistical analyses
We used the linear regression model of the R minﬁ package to
assess the genome-wide association between the DNA methyla-
tion status of CpG-SNPs and age of onset in C9orf72 patients,
as well as to evaluate the false discovery rate to generate ad-
justed q-values (Zhang et al., 2017). We used a Manhattan plot
to prioritize signiﬁcant variants (P50.01 and q50.05) for
further genetic study, and a Q-Q plot to highlight potential
confounders using the R qqman package (Turner, 2018).
To assess if genotypes affect age of onset, we used a Cox
proportional hazard regression model (R survival and survminer
packages) (Grambsch, 2000) adjusting for sex, rs1990622 geno-
types, disease phenotypes, and censoring age of last follow-up
for the 22 currently asymptomatic C9orf72 carriers. To adjust
for relatedness in the Cox proportional hazard regression ana-
lysis of the discovery cohort, we created an indicator number
for each family; then used the coxph function of the R coxme
package with a frailty approach (Ripatti and Palmgren, 2000).
The hazard ratio (HR) with 95% conﬁdence interval (CI) is
presented. To analyse the association between genotypes and
age of onset in the C9orf72 disease subgroups, we used multi-
variate linear regression with an additive, dominant or recessive
model adjusting for sex, rs1990622 genotypes, or DNA methy-
lation age-acceleration. We also used multivariate linear regres-
sion to analyse the association between genotypes and age of
onset in C9orf72 negative disease subgroups (adjusting for sex).
We present the linear regression coefﬁcient (B) with standard
error (SE) and percentage of response variance explained by
the linear regression model (r2). Results of additive model
were presented, unless otherwise speciﬁed.
We used a meta-analysis (R metafor package) with a ﬁxed-
effect model to assess the pooled effect size of the Cox regres-
sion coefﬁcient (logHR) from the discovery and replication
stages (Trinh et al., 2016). We performed a trend analysis
using the Cochran–Armitage test to analyse if rs9357140
genotypes are associated with C9orf72 disease subgroups. A
non-parametric Mann-Whitney U-test or Kruskal-Wallis test
was used to assess differences in age of onset or gene expres-
sion among two or more groups where appropriate. Sex and
rs1990622 genotype adjusted P-values are shown, unless
otherwise speciﬁed. The results with P5 0.05 were accepted
as statistically signiﬁcant.
Data availability
The data that support the ﬁndings of this study are available
on request from the corresponding authors (E.R., M.Z.). The
data are not publicly available because of information that
could compromise the privacy of the research participants.
Results
Epigenetic analysis suggested
CpG-SNPs associated with age of
onset
The study design is presented in Fig. 1. First, we estimated the
association between age of onset in a Canadian cohort of 46
unrelated C9orf72 patients and DNA methylation levels at
7603 common CpG-SNPs available on the 450K BeadChip.
Age of onset was signiﬁcantly associated with DNA methyla-
tion levels (q50.05) at three CpG-SNPs (rs12763379 on
10q24.2; rs9357140 and rs2143466 on 6p21.3):
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P = 9.6  106, P = 6.0  106 and P = 1.8  105, respect-
ively (Fig. 2A and Supplementary Table 7). However,
rs12763379 in PYROXD2 was removed from follow-up
study because of its overlap with insertion/deletion variations
and single tandem repeats precluding reliable genotyping.
Genetic association study confirmed
the association between rs9357140/
rs2143466 and age of onset
Multivariate linear regression suggested that rs9357140
genotypes control the gain or loss of DNA methylation
at CpG-site cg18698799 (P5 1.0  106), thereby under-
lying the association with age of onset: adjusted
P = 2.2  105, B = 7.01 (SE: 1.47) (Fig. 2B). The associ-
ation remained signiﬁcant after adjusting for DNA methy-
lation age-acceleration: P = 2.7  104, B = 6.72 (SE: 1.68).
AA-carriers have signiﬁcantly lower DNA methylation
levels compared to AG-carriers (P = 2.2  105, Mann-
Whitney U-test) or GG-carriers (P = 4.7  105, Mann-
Whitney U-test); mean b-value: 0.04 (AA-carriers) versus
0.54 (AG-carriers) versus 0.88 (GG-carriers) (Fig. 2B).
Similar results were observed for rs2143466 (Supplemen-
tary Fig. 1). The Q-Q plot suggested that there are no other
confounders for the association (Supplementary Fig. 2).
Both SNPs belong to a strong 124.7 kb LD-block
(R24 0.8) on chr6:32213638–32338386 containing
two overlapping genes: a long non-coding RNA
(LOC101929163) and C6orf10—an uncharacterized testes-
speciﬁc gene with rs9357140 mapped to intron 9 and
rs2143466 mapped to intron 14 (Fig. 2).
Next, we enlarged our discovery dataset to 144 carriers by
genotyping rs9357140 and rs2143466 in 98 recently col-
lected C9orf72 carriers, including 101 unrelated symptom-
atic carriers and 16 families with 21 symptomatic and 22
asymptomatic C9orf72 carriers (Fig. 1 and Table 1). To
obtain the median age of onset for different SNP genotypes,
we used the Kaplan-Meier estimate, censoring age of last
follow-up for asymptomatic carriers. The median age of
onset difference between rs9357140 AA- and GG-carriers
was 12 years: 67 years for AA (95% CI: 60–71), 59 years
for AG (95% CI: 56–64) and 55 years for GG genotype
(95% CI: 54–60) (Fig. 3A). Cox proportional hazard regres-
sion analysis also revealed that age of onset in C9orf72 car-
riers is signiﬁcantly associated with rs9357140 genotypes:
adjusted P = 1.1  104, HR = 0.43 (95% CI: 0.28-0.66),
suggesting that every A-allele could reduce hazard by 57%
(Fig. 3B and Table 2). A similar association with age of onset
was also observed for rs2143466: adjusted P = 1.1  104,
HR = 0.43 (95% CI: 0.28–0.68) (Supplementary Fig. 3).
The replication study validated the
association between rs9357140/
rs2143466 and age of onset
In the replication stage (Fig. 1 and Table 1), we obtained
genotypes from the IFGC-GWAS (Ferrari et al., 2014) for
10 SNPs tagged by rs9357140 (R24 0.9) (Supplementary
Table 5) for 187 C9orf72 patients with a median age of
onset of 58 years and interquartile range (IQR) of 51–80
years. Cox proportional hazard regression analysis showed
that age of onset was signiﬁcantly associated with
Figure 1 Flow chart of the study design. AO = age of onset.
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Figure 2 Genome-wide DNA methylation analysis of the CpG-SNPs in C9orf72 patients. (A) Manhattan plot presenting the
association between DNA methylation status of CpG-SNPs and age of onset, including a locus on chr6:32160000–32580000 with two age of
onset-associated CpG-SNPs (rs9357140 and rs2143466 indicated by the box). Arrows indicate the transcriptional direction of each gene (50 to
30). ‘Me’ in red represent methylation sites controlled by rs9357140 and rs2143466. The LD block tagged by rs9357140 (R24 0.8) is highlighted in
green. (B) Genotypes of rs9357140 are significantly associated with DNA methylation status: P5 1.0  106, B = 0.39 (SE: 0.01); and age of
onset: P = 2.2  105 adjusted for sex and rs1990622 genotypes, B = 7.01 (SE: 1.47). The dashed line represents the linear regression trend.
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rs9357140: adjusted P = 0.03, HR = 0.79 (95% CI: 0.64–
0.98), suggesting that every A-allele reduced hazard by
21% (Table 2 and Fig. 3). As expected, similar associations
with age of onset were observed for rs2143466: adjusted
P = 0.025, HR = 0.79 (95% CI: 0.64–0.97) (Supplementary
Fig. 3) and for the other eight SNPs within the LD block
listed in Supplementary Table 5 (data not shown).
Meta-analysis revealed overall effect
of rs9357140/rs2143466 on age of
onset
We conducted a meta-analysis of logHR in all 331 C9orf72
carriers using a ﬁxed-effects model and observed that every
Figure 3 The association between rs9357140 genotypes and age of onset in C9orf72 carriers. (A) Kaplan-Meier curve of cumulative
incidence of disease onset in the discovery cohort (n = 144) stratified by rs9357140 genotypes. (B) Meta-analysis of the Cox regression coef-
ficient from the discovery cohort (n = 144) and the replication cohort (n = 187). The regression coefficient equals logHR.
Table 2 The Cox proportional hazard regression results
for the association between the rs9357140 genotypes
and age of onset in the discovery and replication
cohorts
Discovery
(n = 144)
Replication
(n = 187)
HR (95% CI) 0.59 (0.45–0.77) 0.79 (0.64–0.98)
P-value for AA versus
AG versus GG
0.0001 0.029
Adjusted HR (95% CI)* 0.43 (0.28–0.68) 0.79 (0.64–0.98)
Adjusted P-value for
AA versus AG versus GG*
0.00011 0.03
*The hazard ratio (HR) and P-value was adjusted for sex, rs1990622 genotypes, disease
phenotypes and family relationship in the discovery stage. HR was adjusted for sex,
rs1990622 genotypes and disease phenotypes in the replication stage.
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A-allele of rs9357140 reduced hazard by 30% (pooled
HR = 0.70, P = 0.0003) (Fig. 3B). Again, a similar effect
was observed for rs2143466 (pooled HR = 0.70,
P = 0.0002) (Supplementary Fig. 3). The association between
age of onset and rs9357140 was also signiﬁcant in 304 un-
related C9orf72 patients: adjusted P = 2.3  106, B = 3.2
(SE: 0.67) (Supplementary Table 1). The median age of
onset of rs9357140 AA-carriers was 6 years later than GG-
carriers: 62 years (IQR: 57–68) versus 56 years (IQR: 50–62).
Subgroup analyses of the association
between rs9357140 and age of onset
The association between age of onset and rs9357140 was
evident in unrelated C9orf72 patients with either pure ALS
(n = 59; adjusted P = 0.002, B = 4.97, SE: 1.53) or pure
FTD (n = 174; adjusted P = 0.0008, B = 2.82, SE: 0.83),
but not in patients with FTD-ALS (n = 71; adjusted
P = 0.125, B = 2.63, SE: 1.69) (Supplementary Table 1
and Supplementary Fig. 4A–C). A similar result was
observed for rs2143466 (Supplementary Fig. 4D–F).
Notably, we found no signiﬁcant difference in age of
onset among patients affected by pure ALS, pure FTD or
FTD-ALS; or ALS/FTD subtypes (bulbar ALS, limb ALS,
unspeciﬁed ALS, bvFTD, semantic dementia, PNFA, un-
speciﬁed FTD): P40.05, Kruskal-Wallis test
(Supplementary Fig. 5). Multivariate linear regression ana-
lysis in different disease subtypes revealed that age of onset
was associated with rs9357140 genotypes in limb ALS
(n = 35) and bulbar ALS (n = 23) under a dominant
model (adjusted P50.05), and bvFTD (n = 157) under a
recessive model (adjusted P5 0.05), but not in FTD-ALS
patients (n = 71) (Supplementary Table 1).
To evaluate if rs9357140 genotypes modify disease
phenotypes, we performed a trend analysis using the
Cochran–Armitage test to analyse the association between
rs9357140 genotypes and C9orf72 disease phenotypes
(ALS versus FTD, ALS versus FTD-ALS, or FTD versus
FTD-ALS) under an additive model (AA versus AG versus
GG) (Supplementary Table 8); and found no statistically
signiﬁcant results (P40.05).
Age of onset in C9orf72 negative
patients is associated with rs9357140
We analysed 2634 C9orf72-negative patients with ALS,
FTD or FTD-ALS (Supplementary Table 2), and found a
signiﬁcant association between rs9357140 genotypes and
age of onset (adjusted P = 0.007 for recessive model)
(Supplementary Table 2). Subgroup analysis detected a sig-
niﬁcant association only in the largest subgroup of FTD
patients (n = 2142, adjusted P = 0.01 for recessive model)
with a small effect size (B = 1.44, SE: 0.55) (Supplementary
Table 2). The association is evident in the bvFTD patients
(n = 1364, adjusted P = 0.035 for recessive model), but not
the other smaller FTD subtypes (Supplementary Table 2).
We also observed that age of onset differed signiﬁcantly
among the FTD subtypes (P5 0.01, Kruskal-Wallis test).
Cox proportional hazard regression analysis revealed that
the AA-genotype is associated with age of onset [P = 0.036,
adjusted for sex and FTD subtype; HR = 0.94 (95% CI:
0.88–0.99)], suggesting that the AA-genotype could
reduce hazard by 6% relative to the GG- and AG-geno-
types. Kaplan-Meier estimate analysis revealed that AA-car-
riers have a slightly later median age of onset (63 years in
AA-carriers versus 62 years in GG + AG-carriers) (Fig. 4).
A similar association with age of onset was also observed
for rs2143466 in the C9orf72 negative FTD patients:
P = 0.036, adjusted for sex and FTD subtype; HR = 0.94
(95% CI: 0.88–0.99).
The expression of HLA-DRB1 and
LOC101929163 is associated with
rs9357140
Since rs9357140 and rs2143466 control the loss or gain of
CpG-sites and therefore DNA methylation levels (Fig. 2),
we hypothesized that CpG-SNPs at the C6orf10/
LOC101929163 locus may modulate age of onset by reg-
ulating gene expression. We used the public eQTL dataset
of 48 types of human tissue (GTEx portal) to analyse if
genotypes of the top-signiﬁcant tagging SNP (rs9357140)
are associated with the expression of nearby genes (10 top-
signiﬁcant hits are shown in Supplementary Table 9).
Among brain tissues, the A-allele of rs9357140 was asso-
ciated with reduced expression of the LOC101929163
(P = 7.6  106, NES = 0.66 in the nucleus accumbens,
part of the basal ganglia; Supplementary Fig. 6A); and
HLA-DRB1, encoding major histocompatibility complex,
class II, DR beta 1 (P = 4.1  106, NES = 0.42 in the
frontal cortex; Supplementary Fig. 6B).
To validate the link between rs9357140 genotypes and
HLA-DRB1 expression, we conducted quantitative RT-
PCR using frontal cortex from 25 unrelated ALS cases
(Supplementary Fig. 6C). Mann-Whitney U-test conﬁrmed
that AA-carriers had signiﬁcantly lower HLA-DRB1 expres-
sion compared to AG-carriers (P = 0.001) or GG-carriers
(P = 0.000003). Of note, C9orf72 expression did not differ
among the rs9357140 genotypes (P4 0.05, Mann-Whitney
U-test, Supplementary Fig. 7) and was not correlated with
HLA-DRB1 expression (adjusted P = 0.23, linear regression).
Bioinformatics analysis predicted
multiple DNase I hypersensitivity
sites within the LD-block associated
with age of onset
The LD-block associated with age of onset contains 196
known variants tagged by rs9357140 (R240.8), including
ﬁve missense substitutions with minor allele frequencies of
0.36–0.38 and conﬂicting functional predictions by
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PolyPhen-2 and SIFT (Supplementary Table 10). Since
C6orf10 is expressed mainly in testes, its coding variability
is likely not relevant to C9orf72 pathology. We found no
transcriptional factor binding sites mapped to any of the
196 SNPs; however, 12 of these SNPs are located at DNase
I hypersensitivity sites; including rs9268000 (78 kb up-
stream of rs9357140) with a high cluster score of 1000
(Supplementary Table 10). These results suggest that age
of onset modiﬁers of C9orf72 disease could be associated
with DNase I hypersensitivity sites and HLA-DRB1 expres-
sion (250 kb away from the investigated LD-block, Fig. 2).
Discussion
The current study combined epigenetic and genetic data to
detect functional variants associated with age of onset in a
large dataset of 331 C9orf72 carriers. A DNA methylation
study of CpG-SNPs in the discovery stage enabled prioritiz-
ing age of onset modiﬁers linked to DNA methylation status
for further genetic investigation. Such a novel strategy has
the advantage of reducing noise from GWAS signals. Indeed,
CpG-SNPs could help rank GWAS hits (Gagliano et al.,
2016), as they are important elements of methylation quan-
titative trait loci (Hannon et al., 2016). Our genome-wide
DNA methylation analysis of CpG-SNPs followed by a gen-
etic association study of the discovery and replication
C9orf72 cohorts revealed that age of onset is associated
with SNPs within a 124.7 kb LD-block tagged by
rs9357140. Overall, every A-allele of rs9357140 may
reduce hazard by 30% (the median age of onset of AA-car-
riers was 6 years later than GG-carriers). The genotypes of
rs9357140 were also moderately associated with age of
onset in C9orf72-negative patients although the effect size
was small (e.g. the median age of onset in AA-carriers af-
fected by FTD was 1 year later than GG-carriers).
Recently, a key tool for connecting phenotypes to genetic
variations has emerged from gene expression studies. Since
the locus with signiﬁcant SNPs may not be the actual dis-
ease-related target, cis-acting eQTLs can provide a mech-
anistic link between SNPs and the biological processes they
affect (GTEx Consortium et al., 2017). In our study, the
minor A-allele of rs9357140 (top-signiﬁcant SNP within the
C6orf10/LOC101929163 locus) is associated with reduced
brain expression of LOC101929163 (in nucleus accum-
bens) and HLA-DRB1 (in frontal cortex), while the
major G-allele is associated with their increased expression
(Supplementary Fig. 6). Future functional studies have to
investigate if the non-coding RNA LOC101929163 is a
modulator of HLA-DRB1 expression (e.g. affecting tran-
scriptional factors relevant to HLA-DRB1). The major
histocompatibility complex class II protein HLA-DR is
implicated in neurodegenerative diseases as a marker of
activated microglia (Walker and Lue, 2015) and is import-
ant in initiating immune responses by presenting peptides
derived not only from exogenous but also endogenous pro-
teins, such as peptides resulting from autophagy of intra-
cellular proteins by lysosomes (Dengjel et al., 2005).
Our results support the notion that microglial/autophagy
pathways play key roles in modulating C9orf72 disease, the
pathogenesis of which might involve both gain and loss of
function mechanisms (Hardy and Rogaeva, 2014). Normal
function of C9orf72 is essential for the lysosome/autopha-
gosome pathway and immune responses in macrophages or
microglia (O’Rourke et al., 2016; Shi et al., 2018). For
instance, transcriptome and histologic analyses of
C9orf72 carriers support the idea that decreased C9orf72
expression leads to altered microglial function and neuroin-
ﬂammation (O’Rourke et al., 2016), while increased
C9orf72 levels could be neuroprotective (McGoldrick
et al., 2018; Shi et al., 2018). It is important to investigate
if rs9357140 GG-carriers, which have an earlier age of
onset and upregulated HLA-DRB1, are in a more pro-in-
ﬂammatory state (e.g. by microglia) than AA-carriers.
Our survey of the literature and the GWAS catalogue
database (https://www.ebi.ac.uk/gwas/) revealed that SNPs
within or close to the C6orf10/LOC101929163 locus
(Supplementary Fig. 8) are associated with autoimmune
disorders (multiple sclerosis, rheumatoid arthritis, systemic
sclerosis, Grave’s disease and asthma), as well as neurode-
generative diseases (FTD, Parkinson’s disease and
Alzheimer’s disease) (Lambert et al., 2013; Ferrari et al.,
2014; Lu et al., 2017), highlighting the role of the
immune system in neurodegeneration (Supplementary
Table 11). Notably, several dementia genes are linked to
microglia/immune function (e.g. TREM2 and CD33)
(Lambert et al., 2013). Our study of C9orf72-negative pa-
tients suggests that the C6orf10/LOC101929163 locus
could be a modest age of onset modiﬁer for the general
Figure 4 Kaplan-Meier curve of cumulative incidence of
disease age of onset in 2142 C9orf72-negative patients with
FTD stratified by rs9357140 genotype (AA versus
GG + AG).
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population of FTD patients. Intriguingly, another two SNPs
(rs9268877 and rs9268856) near this locus have been re-
ported in a case-control GWAS as modiﬁers of FTD risk
(Ferrari et al., 2014). Of note, rs9357140 is not in LD with
rs9268877 and rs9268856 representing an independent as-
sociation signal (Supplementary Table 11), yet the mechan-
ism behind the association with age of onset or disease risk
could be similarly pointing to the functional signiﬁcance of
the HLA-DRA/HLA-DRB5 locus.
Notably, age of onset estimation is more objective for ALS
(self-reported) than FTD (reported by family members)
(Pottier et al., 2018). Hence, the less signiﬁcant result in
the replication C9orf72 cohort enriched in FTD patients
(72.7% versus 27.8% in the discovery stage) may be ex-
plained by a less accurate age of onset estimation
(Supplementary Table 12). In addition, the subgroup ana-
lysis could be further complicated by the less accurate esti-
mation of age of onset for the complex FTD-ALS phenotype
and reduced statistical power for the smaller subgroup.
One of the limitations of our study is the lack of uniﬁed
deep phenotyping for each patient and healthy control
data, however our ﬁndings set the basis for future research
(e.g. aimed at investigating the link between CpG-SNPs and
disease phenotype, risk, progression or severity). Another
limitation is the absence of information on the expansions
size in our study participants, because C9orf72 genotyping
was done by repeat-primed PCR. This is of note, since
repeat length examined by Southern blot was inversely cor-
related with age of onset (van Blitterswijk et al., 2013), and
the clinical data support disease anticipation in C9orf72
families, which is evident by an earlier age of onset
across successive generations (van Blitterswijk et al.,
2013; Xi et al., 2015a; Van Mossevelde et al., 2017).
However, C9orf72 repeat expansions are difﬁcult to size
accurately by Southern blot because of their large size (up
to several thousand repeats) and somatic mosaicism mask-
ing the true length of the expansion (Xi et al., 2015a;
McGoldrick et al., 2018). It would also be important to
understand the genetic-epigenetic links across human tis-
sues relevant to neurodegenerative disorders, since DNA
methylation changes reﬂect the complex interactions
between genes, environmental factors, and ageing
(Zhang et al., 2016).
Our ﬁndings suggest that CpG-SNPs at the C6orf10/
LOC101929163 locus might modify age of onset in
C9orf72 carriers belonging to the entire ALS-FTD spectrum
by controlling DNA methylation and gene expression (e.g.
HLA-DRB1). CpG-SNPs at the C6orf10/LOC101929163
locus might also be age of onset modiﬁers for general FTD
patients to a lesser extent. Understanding the functional
mechanisms of the C6orf10/LOC101929163/HLA-DRB1
pathway (e.g. to investigate if the non-coding RNA
LOC101929163 is a modulator of HLA-DRB1 expression)
might prove critical for identifying biomarkers and/or de-
signing drugs to modify age of onset in C9orf72 driven
disease. Finally, the detected CpG-SNPs could be used to
better predict age of onset in C9orf72 asymptomatic
carriers in preventive clinical trials (e.g. based on the
Genetic Frontotemporal dementia Initiative study) (Rohrer
et al., 2015), for designing conditional and/or modiﬁers
studies in the sporadic FTLD spectrum, such as based on
IFGC related projects (https://ifgcsite.wordpress.com/) and
for genetic counselling.
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